Omeros (NASDAQ:OMER) had its price objective lifted by Bank of America from $2.44 to $4.00 in a report issued on Wednesday morning, The Fly reports.

A number of other brokerages have also recently commented on OMER. Zacks Investment Research upgraded Omeros from a sell rating to a hold rating in a research report on Wednesday, November 15th. Wedbush reiterated an outperform rating and set a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Maxim Group reiterated a buy rating and set a $24.00 target price on shares of Omeros in a research report on Monday, November 6th. HC Wainwright set a $30.00 target price on Omeros and gave the stock a buy rating in a research report on Tuesday, January 23rd. Finally, ValuEngine upgraded Omeros from a sell rating to a hold rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $30.38.

Shares of Omeros (NASDAQ OMER) opened at $11.25 on Wednesday. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. The company has a market capitalization of $558.18, a PE ratio of -9.02 and a beta of 3.30. Omeros has a 1 year low of $10.52 and a 1 year high of $27.09.

Several large investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC grew its position in shares of Omeros by 20.7% during the second quarter. Voya Investment Management LLC now owns 19,300 shares of the biopharmaceutical company’s stock worth $384,000 after purchasing an additional 3,304 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Omeros by 0.7% during the third quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock worth $10,397,000 after purchasing an additional 3,430 shares in the last quarter. Nwam LLC grew its position in shares of Omeros by 10.1% during the third quarter. Nwam LLC now owns 46,520 shares of the biopharmaceutical company’s stock worth $1,006,000 after purchasing an additional 4,280 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its position in shares of Omeros by 35.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 18,808 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 4,940 shares in the last quarter. Finally, First Interstate Bank purchased a new stake in shares of Omeros during the third quarter worth about $108,000. Hedge funds and other institutional investors own 50.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Omeros (OMER) PT Raised to $4.00” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/15/omeros-omer-pt-raised-to-4-00.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

The Fly

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.